• About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • OncoFAP-Radio Conjugates
    • OncoFAP-Drug Conjugate
    • Onco IX (PHC-102, Imaging)
  • Press releases & Events
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering
  • About us
    • Profile
    • Board of Directors
    • Scientific Directors
  • Our Science
    • Strategy
    • Activities and Technologies
  • Pipeline
    • Pipeline
    • Onco IX (PHC-102, Imaging)
    • OncoFAP-Radio Conjugates
    • OncoFAP-Drug Conjugate
  • Press releases & Events
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering

Philogen receives authorisation to initiate new study in France to evaluate Nidlegy™ in several non-melanoma skin cancers

by mfantozzi | Feb 17, 2022 | 2022, Press Releases, Scientific

More details

Philogen announces publication of PET clinical data with proprietary ultra-high affinity FAP-targeting small molecule ligand (OncoFAP)

by mfantozzi | Jan 7, 2022 | 2022, Press Releases, Scientific

More info here

Philogen announces new collaboration with Janssen to discover small molecule therapeutics

by mfantozzi | Nov 24, 2021 | 2021, Press Releases, Scientific

More datails

Philogen provides Corporate Update

by mfantozzi | Nov 12, 2021 | 2021, Press Releases, Scientific

Philogen to hold a Webinar at 11 am EST / 4 pm GMT / 5 pm CET on Friday 12th November 2021, Click here to view Press Release 12-11-2021

Philogen to attend the Cytokine-Based Cancer Immunotherapies Summit on November 30-December 2 , 2021

by mfantozzi | Nov 4, 2021 | 2021, Past Events, Scientific

Dario Neri, co-founder, CEO and CSO, is giving a presentation to address the question on how to achieve the therapeutic dose at the tumor site with cytokine-based targeted products. Roberto De Luca, Head of Antibody Therapeutics at Philogen, is also giving a...

Philogen announces Philochem Patent Upheld

by mfantozzi | Oct 15, 2021 | 2021, Press Releases, Scientific

Philogen announces that Philochem’s European Patent 3083957 relating to important features of proprietary DNA-encoded chemical libraries (“ESAC 2+1” technology) was upheld after Oral Proceedings in front of the Opposition Division at the European Patent Office. Read...
« Older Entries
Next Entries »

Recent Posts

  • Philogen announces new publication in Nature Chemistry
  • Philochem to attend the 71st American Society for Mass Spectrometry Conference on June 4-8, 2023
  • Philogen to attend AACR Annual Meeting in Orlando on April 14-18, 2023
  • Philogen to attend Mid & Small | London 2023 Conference on April 20, 2023
  • Philogen to attend 19th EADO Congress on April 20-22, 2023

Recent Comments

    Philochem AG ©

    Privacy / Contacts

    • Follow

    Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch